Home/Pipeline/Avoralstat

Avoralstat

Diabetic Macular Edema (DME)

Phase 2Investigational (Non-Core)

Key Facts

Indication

Diabetic Macular Edema (DME)

Phase

Phase 2

Status

Investigational (Non-Core)

Company

BioCryst Pharmaceuticals

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a mission-driven, commercial-stage biotech focused on delivering first-in-class or best-in-class oral therapies for rare diseases with significant unmet need. Its strategic evolution from a discovery entity was cemented by the 2020 FDA approval of ORLADEYO® (berotralstat), a once-daily oral prophylactic for HAE, establishing a sustainable revenue base. The company leverages its proprietary structure-guided drug design platform to build a pipeline in HAE and complement-mediated diseases, aiming to deepen its market penetration and expand into new therapeutic areas like Netherton syndrome.

View full company profile

Therapeutic Areas

Hereditary Angioedema (HAE)Complement-Mediated Disorders Rare Dermatological Diseases

Other Diabetic Macular Edema (DME) Drugs

Drug	Company	Phase	Status
UBX1325 (foselutoclax)	Unity Biotechnology	Phase 2b	Discontinued
CLS-AX	Clearside Biomedical	Preclinical	Research
OCS-01	Oculis	Phase 3	Active
Oral K9	Inflammasome Therapeutics	Phase I	Active
Ixoberogene soroparvovec (Ixo-vec)	Adverum Biotechnologies	Phase 2	Deprioritized/Completed
Allgenesis Phase 2 DME Trial Support	Voxeleron	Phase 2	Active
DURAVYU™ (EYP-1901)	EyePoint Pharmaceuticals	Phase 3	Pivotal Trials Underway (COMO & CAPRI)
Sozinibercept (OPT-302)	Opthea	Phase 2	Completed/De-prioritized
ONS-5010 / LYTENAVA™ (bevacizumab-vikg)	Outlook Therapeutics	Phase 3	Active (NORSE SEVEN)